# Response to Anti-hypertensives in Pregnant and Postpartum Patients

Study · id `cardio:ct-nct03506724` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03506724](<https://clinicaltrials.gov/study/NCT03506724>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03506724

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.

## Technical summary

Registry record NCT03506724. Randomized; no masking; primary purpose treatment. Start 2017-09-11 (actual); primary completion 2019-04-05 (actual). Results posted on 2021-05-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 109 participants (enrolled count; ClinicalTrials.gov record NCT03506724, source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)
- Started: 2017-09-11 (actual) (ClinicalTrials.gov record NCT03506724, source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)
- Primary completion: 2019-04-05 (actual) (ClinicalTrials.gov record NCT03506724, source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)
- Completion: 2019-04-05 (actual) (ClinicalTrials.gov record NCT03506724, source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)
- Results first posted: 2021-05-24 (ClinicalTrials.gov record NCT03506724, source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03506724, source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03506724-2021-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Response to Anti-hypertensives in Pregnant and Postpartum Patients
- Condition: Hypertension in Pregnancy
- Condition: Preeclampsia
- Intervention (Drug): Nifedipine
- Intervention (Drug): Labetalol
- Lead sponsor: Icahn School of Medicine at Mount Sinai
- Lead sponsor class: OTHER
- Collaborator: Mount Sinai Hospital, New York
- Collaborator class: OTHER
- Collaborator: Maimonides Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Nifedipine (`cardio:nifedipine`)
- Registry lists this organization as the lead sponsor: Icahn School of Medicine at Mount Sinai (`cardio:org-icahn-school-of-medicine-at-mount-sinai`)
- Registry lists this organization as a collaborator: Mount Sinai Hospital, New York (`cardio:org-mount-sinai-hospital-new-york`)

## Provenance

Content hash: 8df8ad0150d12aa3c443490399ff3038822c67e0afc7625f70ac7a02e2db3126
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
